NattoPharma

News and Media

Event calendar

2017

New MenaQ7/Omega-3 Product By Wiley’s Finest: NattoPharma Announces

OSLO, NORWAY AND METUCHEN, NJ – (March 14, 2017) Nattopharma is excited to announce its visionary partner, Ohio-based Wiley’s Finest™ Wild Alaskan Fish Oil, is preparing to launch its Adult EPA and DHA Omega-3 formula featuring MenaQ7® Vitamin K2 as MK-7. The Adult formula is the second product from Wiley’s Finest featuring MenaQ7®.

Read more »

NattoPharma Named Partner For Horizon 2020 EU Research Grant

OSLO, NORWAY and METUCHEN, NJ (February 7, 2017) – NattoPharma’s International Research Network, coordinated by Queen Mary University of London, has been awarded with a highly competitive ITN research grant from European Commission’s research program Horizon 2020. Other partners of the network are four highly ranked research university departments in Europe [University of Maastricht, University College Dublin (part of the national University of Ireland), Ludvig-Maximilians-Universitaet Muenchen, and Karolinska Institutet in Stockholm] and the independent life science medical research charity in the UK, the Medical Research Council Technology. The grant NattoPharma participates in is called “EVOLuTION” (European Vascular Interventions and Therapeutic Innovation Network), and the money will be utilized to provide training for 11 early stage researchers (ESRs) in the management of chronic diseases in the field of cardiovascular disease.

Read more »

Two New Studies: Vitamin K Need Linked to Arterial Calcification and Stiffness

OSLO, NORWAY and METUCHEN, NJ (5 January 2017) – Nephron¸ a kidney research and clinical journal, and the American Journal of Hypertension have each just published new papers linking the vitamin K-dependent protein MGP (matrix GLA-protein) to vascular calcification, vascular and arterial stiffness. The two studies, “Correlations of Plasma Desphosphorylated Uncarboxylated Matrix Gla Protein with Vascular Calcification and Vascular Stiffness in Chronic Kidney Disease,” and “Inactive Matrix Gla-Protein and Arterial Stiffness in Type 2 Diabetes Mellitus,” respectively, have linked increased risk of arterial calcification and stiffness to a lack of the active protein. One set of authors even recommended supplementation of vitamin K as a potential treatment.

 

Read more »

For the Press

Press inquire:

Kate Quackenbush
Director of Communications
kate.quackenbush@nattopharma.com
(+1) 609-454-2992 x 220

NattoPharma contact information:
Main office: Lilleakerveien 2B, 0283 Oslo,Norway
North American Subsidary: 328 Amboy Ave.,Ste. D,Metuchen, NJ 08840
Tel: (+47) 40 00 90 08
Tel: (+1) 609-454-2992
E-mail: info@nattopharma.com
E-mail: info.US@nattopharma.com
Created by:
Nutricon logo.
Search term:
Newsletter